Novo Nordisk makes the wildly popular GLP-1 drug semaglutide which it sells under the brand name Wegovy for weight-loss and ...

Novo Nordisk's shares saw an uptick following the FDA's approval of Wegovy, its flagship drug, to treat a severe fatty liver disease.

Investors bought in after the company got U.S. approval for its weight-loss drug Wegovy to treat a serious liver ...

Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated ...

FDA approves Novo Nordisk's Wegovy for MASH with liver fibrosis, supported by ESSENCE trial data as the company projects ...

Echosens, the leader in non-invasive liver diagnostics, and Novo Nordisk are strengthening their aligned efforts to combat steatotic liver disease, following the U.S. Food and Drug Administration's ...

Shares in Novo Nordisk rose as much as 5% in early European trading Monday, regaining some ground after losing more than half of their value over the past year.